SCWorx Corp. filings document the regulatory record for a healthcare SaaS data management company and its common stock. The company’s 8-K reports cover Nasdaq minimum-bid-price notices, reverse stock split actions, warrant inducement agreements, and other material events tied to capital structure and listing compliance.
Its registration and proxy filings describe securities offerings, common stock and warrant issuance, shareholder voting matters, director elections, executive compensation advisory votes, auditor ratification, and Nasdaq Rule 5635(d) share-issuance approvals. These disclosures also frame governance, capital authorization, and financing terms for the business.
SCWorx Corp. received notice from Nasdaq on April 7, 2026 that its common stock will be delisted from the Nasdaq Capital Market for failing to meet the minimum bid price requirement of $1.00 per share under Nasdaq Rule 5550(a)(2) by the April 6, 2026 deadline.
Nasdaq plans to suspend trading on April 14, 2026 and file a Form 25-NSE to remove the stock from listing and registration, though SCWorx has appealed this determination to a Nasdaq hearings panel. To address the deficiency, the company amended its certificate of incorporation to implement a 1-for-15 reverse stock split, combining every 15 outstanding shares into one share, effective at the open of trading on April 10, 2026.
To regain compliance, the post-split common stock must trade at or above $1.00 per share for ten consecutive trading days. The company states it expects to regain compliance as a result of the reverse split but cautions there is no assurance it will succeed or prevail in its appeal, and that failure to remain listed on Nasdaq could adversely affect the company.
SCWorx Corp. has approved a 1-for-15 reverse stock split of its common stock by amending its certificate of incorporation. Every 15 shares of outstanding common stock will be combined into one share. The reverse split is expected to be effective at the start of trading on April 10, 2026.
The company is undertaking this reverse split to help regain compliance with the Nasdaq Stock Market’s minimum bid price rule, which requires its common stock to trade at or above $1.00 per share for ten consecutive trading days. SCWorx notes there is no assurance this step will restore compliance, and if compliance is not regained, its common stock will be delisted from Nasdaq.
SCWorx Corp. reports declining 2025 results and growing financial strain. Revenue slipped about 4% to $2,877,629 from $2,989,599 in 2024, while net loss widened sharply to $4,444,109 from $1,136,225. The company reports an accumulated deficit of $35,420,175 and acknowledges substantial doubt about its ability to continue as a going concern, citing ongoing losses and challenges raising capital.
At December 31, 2025, SCWorx had 9 employees and focuses on SaaS data-normalization and interoperability solutions for U.S. hospitals. As of June 30, 2025, non‑affiliate market value was about $2.7 million, and as of March 31, 2026 there were 15,999,423 common shares outstanding, with 54,055,187 shares issuable under warrant agreements. The company is working to regain Nasdaq’s $1.00 minimum bid price and may implement a reverse stock split if needed.
SCWorx Corp. investors Iroquois Capital Management, Richard Abbe, and Kimberly Page report their beneficial ownership of the company’s common stock in an amended Schedule 13G as of December 31, 2025. Iroquois Capital Management and Kimberly Page each report beneficial ownership of 960,140 shares, representing 5.7% of the class. Richard Abbe reports beneficial ownership of 1,153,662 shares, or 6.8% of the class.
These positions include shares issuable from warrants and convertible notes that are subject to 4.99% and 9.99% Beneficial Ownership Blockers, which limit how much can be converted or exercised at any time. The reported percentages are calculated using 15,826,834 shares outstanding as of September 30, 2025. The filers state the securities are not held to change or influence control of SCWorx.
SCWorx Corp. is registering 53,220,845 shares of common stock for resale by existing investors, tied to prior convertible notes and warrant financings. The company will not receive proceeds from these resale transactions, but could receive up to approximately $16.5 million if related warrants are exercised for cash. SCWorx had 15,826,834 common shares outstanding as of January 6, 2026, while a large pool of additional shares is issuable under outstanding warrants, creating substantial potential dilution.
The filing highlights a weak financial position: 2024 revenue fell about 21% to $2,989,599, with a 2024 net loss of $1,136,225 and an accumulated deficit of $30,976,066 at year-end. For the nine months ended September 30, 2025, the company lost $3,694,927, used about $1,414,534 in operating cash, and held only $684,000 of cash, leading auditors to express substantial doubt about its ability to continue as a going concern.
The prospectus also discloses a Nasdaq minimum bid price deficiency. SCWorx has until April 6, 2026 to regain compliance, likely via a reverse stock split, and warns that failure, especially combined with significant warrant overhang, could result in delisting and make future capital raises more difficult.
SCWorx Corp. reported Q3 2025 results. Revenue was $705,799, down modestly from $759,724 a year ago, while cost controls lifted gross profit to $251,927 from $132,576. Operating loss narrowed to $138,857 from $393,498, but higher non‑cash interest and debt discount amortization drove other expense to $1,173,682, resulting in a net loss of $1,312,539 versus $424,963.
For the nine months, revenue was $2,108,730 versus $2,313,850, and net loss widened to $3,694,927 from $940,935, largely tied to financing-related charges. Cash increased to $684,295 from $106,654, aided by $1,992,175 in net financing cash inflows, including warrant exercises. Deferred revenue was $399,000, and stockholders’ equity rose to $5,997,330.
The company disclosed substantial doubt about its ability to continue as a going concern. Nasdaq granted a 180‑day extension to regain the $1.00 minimum bid price, now through April 6, 2026. Disclosure controls were deemed not effective due to design deficiencies and lack of segregation of duties. Shares outstanding were 15,826,834 as of November 12, 2025.
SCWorx Corp. filed its definitive proxy for the annual meeting on December 8, 2025. Shareholders will vote on four director seats, an advisory say-on-pay, and ratifying Astra Audit & Advisory as auditor.
The proxy seeks approvals that enable significant financing activity. Proposal 4 asks to approve the issuance of shares upon exercise of January 2025 Private Investment Warrants with a $0.3496 exercise price and 4.99%/9.99% ownership caps, citing Nasdaq Rule 5635(d); the company notes potential cash proceeds if exercised for cash and warns of material dilution. Proposal 5 covers a September 2025 warrant inducement: holders exercised 2,064,000 existing warrants at $0.3496 and received 4,128,000 reload warrants at $0.31004, exercisable after shareholder approval.
Proposal 6 requests pre-approval for a potential $1.5 million future notes-and-warrants financing, with up to 6,250,000 conversion shares and warrants initially exercisable for up to 30,000,000 shares, subject to anti-dilution features. Proposal 7 seeks to increase authorized common shares from 45,000,000 to 150,000,000. Proposal 8 asks to adopt a 2025 Equity Incentive Plan reserving 10,000,000 shares. Record date is October 10, 2025; 12,105,650 common shares were outstanding, plus 39,810 Series A Preferred (1,138,730 as-converted voting shares).
SCWorx Corp. set its annual meeting for December 8, 2025 to vote on eight proposals, including director elections, an advisory say‑on‑pay, and ratification of Astra Audit & Advisory, LLC as auditor. The record date is October 10, 2025.
Key capital items seek approval under Nasdaq Rule 5635(d): (1) issuance upon exercise of January 2025 Private Investment Warrants, covering 21,988,638 shares at a $0.3496 exercise price with 4.99%/9.99% beneficial ownership limits; (2) a September 17, 2025 warrant inducement creating 4,128,000 Reload Warrants at $0.31004 after cash exercise of 2,064,000 existing warrants at $0.3496; and (3) a Future Offering of up to $1.5 million in senior secured convertible notes (maximum 6,250,000 conversion shares) and warrants initially exercisable for up to 30,000,000 shares.
Shareholders will also vote to increase authorized common stock from 45,000,000 to 150,000,000 and adopt a 2025 Equity Incentive Plan reserving 10,000,000 shares. Common shares outstanding were 12,105,650 as of October 10, 2025.
SCWorx Corp. (WORX) received a 180-day Nasdaq extension to regain bid-price compliance and now has until April 6, 2026 to meet the $1.00 minimum under Nasdaq Rules 5550(a)(2) and 5810(c)(3)(A). The company will be deemed compliant if its common stock closes at $1.00 or more for at least 10 consecutive business days before that date.
SCWorx states it is monitoring its share price and, if compliance is not regained within the extension, it plans to implement a reverse stock split previously approved by shareholders. If compliance is still not achieved, Nasdaq may issue a delisting notice, which the company could appeal to a hearings panel. The extension has no immediate effect on trading; shares continue on the Nasdaq Capital Market under the symbol WORX.